Effective anti-tumor immunity requires T-cell infiltration, often hindered by cancer cells that inhibit T-cell receptor signaling, reduce T-cell proliferation and cytokine production, and suppress T-cell cytotoxicity through immune checkpoint molecules like PD-1 (encoded by PDCD1) and PD-L1 (encoded by CD274) [44]. This evidence concerns the gene PDCD1 and cancer.